Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;94(4):1696-1700.
doi: 10.1002/jmv.27461. Epub 2021 Nov 25.

Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India

Urvashi B Singh  1 , Mercy Rophina  2   3 , Rama Chaudhry  1 , Vigneshwar Senthivel  2   3 , Kiran Bala  1 , Rahul C Bhoyar  2 , Bani Jolly  2   3 , Nayer Jamshed  4 , Mohamed Imran  2   3 , Ritu Gupta  5 , Praveen Aggarwal  4 , Mohit K Divakar  2   3 , Subrata Sinha  6 , V R Arvinden  2   3 , Anjali Bajaj  2   3 , Afra Shamnath  2 , Abhinav Jain  2   3 ; COVID CBNAAT CORE GROUP; Vinod Scaria  2   3 , Sridhar Sivasubbu  2   3 , Randeep Guleria  7
Affiliations

Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India

Urvashi B Singh et al. J Med Virol. 2022 Apr.

Abstract

Emerging reports of SARS-CoV-2 breakthrough infections entail methodical genomic surveillance for determining the efficacy of vaccines. This study elaborates genomic analysis of isolates from breakthrough infections following vaccination with AZD1222/Covishield and BBV152/Covaxin. Variants of concern B.1.617.2 and B.1.1.7 responsible for cases surge in April-May 2021 in Delhi, were the predominant lineages among breakthrough infections.

Keywords: COVID-19; SARS-CoV-2; genomic analysis; vaccine breakthrough infections; variants of concern.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
(A) Clinical timeline of the samples used in the study in context with the daily surge of cases in Delhi. (B) Phylogenetic context of the SARS‐CoV‐2 isolates analysed in the study. (C) Proportions of lineages in categories of samples with double, single vaccine doses and in controls from a period of March 28, 2021 to April 30, 2021
See this image and copyright information in PMC

References

    1. Mukherjee S, Meacock J, Kissane E, Kissane E, Pal D. SARS‐CoV‐2 re‐infection: development of an epidemiological definition from India. Epidemiol Infect. 2021;82:149‐10. 10.1017/S0950268821000662 - DOI - PMC - PubMed
    1. Philomina J B, Jolly B, John N, et al. Genomic survey of SARS‐CoV‐2 vaccine breakthrough infections in healthcare workers from Kerala, India. J Infect. 2021;83:237‐279. 10.1016/j.jinf.2021.05.018 - DOI - PMC - PubMed
    1. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS‐CoV‐2 variants. N Engl J Med. 2021;384:2212‐2218. 10.1056/NEJMoa2105000 - DOI - PMC - PubMed
    1. Birhane M, Bressler S, Chang G, et al. COVID‐19 vaccine breakthrough infections reported to CDC—United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:70‐793. 10.15585/mmwr.mm7021e3 - DOI - PMC - PubMed
    1. Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diab Metab Syndrome: Clin Res Rev. 2021;15(3):1007‐1008. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts